Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-α-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt/NF-κB signal in JB6 cells

Cancer Letters

Volumn 264, Issue 1, 2008, Pages 93-100

  Xu, Cheng Xiong ^a   Jin, Hua ^a   Chung, Youn Sun ^a   Shin, Ji Young ^a   Woo, Min Ah ^a   Lee, Kee Ho ^b   Palmos, Grace N ^c   Choi, Byeong Dae ^c   Cho, Myung Haing ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Akt; Chondroitin sulfate; iNOS; NF B; Styela clava tunic; VCAM 1

Indexed keywords

CHONDROITIN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASCIDIACEA; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STYELA CLAVA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CHONDROITIN SULFATES; DOWN-REGULATION; EPIDERMIS; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UROCHORDATA; VASCULAR CELL ADHESION MOLECULE-1;

STYELA CLAVA;

EID: 42649098227     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.022     Document Type: Article

References (44)

1. Li Q., Withoff S., and Verma I.M. Inflammation-associated cancer: NF-(B is the lynchpin. Trends Immunol. 26 (2005) 318-325
2. Tan T.T., and Coussens L.M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19 (2007) 209-216
3. Hölschermann H., Schuster D., Parviz B., Haberbosch W., Tillmanns H., and Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 185 (2006) 240-245
4. Karin M., and Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
5. Nam N.H. Naturally occurring NF-κB inhibitors. Mini Rev. Med. Chem. 6 (2006) 945-951
6. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., Toi M., and Umezawa K. Targeting of NF-κB pathways by DHMEQ, a novel inhibitor of breast carcinomas: anti-tumor and anti-angiogenic activity in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
7. Fioravanti A., and Collodel G. In vitro effects of chondroitin sulfate. Adv. Pharmacol. 53 (2006) 449-465
8. Pumphrey C.Y., Theus A.M., Li S., Parrish R.S., and Sanderson R.D. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res. 62 (2002) 3722-3728
9. Cripps J.G., Crespo F.A., Romanovskis P., Spatola A.F., and Fernández-Botrán R. Modulation of acute inflammation by targeting glycosaminoglycan-cytokine interactions. Int. Immunophamacol. 5 (2005) 1622-1632
10. Rolls A., Cahalon L., Bakalash S., Avidan H., Lider O., and Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J. 20 (2006) 547-549
11. Ahn S.H., Jung S.H., Kang S.J., Jeong T.S., and Choi B.D. Extraction of Glycosaminoglycans from Styela clava Tunic. Korean J. Biotechnol. Bioeng. 18 (2003) 180-185
12. Murakami A., Kawabata K., Koshiba T., Gao G., Nakamura Y., Koshimizu K., and Ohigashi H. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. Cancer Res. 60 (2000) 6326-6331
13. Colburn N.H., Wendel E.J., and Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc. Natl. Acad. Sci. USA 78 (1981) 6912-6916
14. Colburn N.H., Former B.F., Nelson K.A., and Yuspa S.H. Tumour promoter induces anchorage independence irreversibly. Nature 281 (1979) 589-591
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunolo. Methods 65 (1983) 55-63
16. Van Horssen R., Ten Hagen T.L., and Eggermont A.M. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11 (2006) 397-408
17. Kabe Y., Ando K., Hirao S., Yoshida M., and Handa H. Redox regulation of NF-κB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal. 7 (2005) 395-403
18. Karin M., and Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
19. Karin M. How NF-κB is activated: the role of the IκBα kinase (IKK) complex. Oncogene 18 (1999) 6867-6874
20. Schieven G.L. The biology of p38 kinase: a central role in inflammation. Curr. Top Med. Chem. 5 (2005) 921-928
21. Romashkova J.A., and Makarov S.S. NF-κB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401 (1999) 86-90
22. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
23. Tong Q., Zheng L., Lin L., Li B., Wang D., and Li D. Hypoxia-induced mitogenic factor promotes vascular adhesion molecule-1 expression via the PI-3K/Akt-NF-(B signaling pathway. Am. J. Respir. Cell Mol. Biol. 35 (2006) 444-456
24. Kang J.S., Yoon Y.D., Han M.H., Han S.B., Lee K., Park S.K., and Kim H.M. Equol inhibits nitric oxide production and inducible nitric oxide synthase gene expression through down-regulating the activation of Akt. Int. Immunopharmacol. 7 (2007) 491-499
25. Shacter E., and Weitzman S.A. Chronic inflammation and cancer. Oncology 16 (2002) 217-226
26. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat. Res. 480-481 (2001) 243-268
27. Chiang Y.M., Lo C.P., Chen Y.P., Wang S.Y., Yang N.S., Kuo Y.H., and Shyur L.F. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, iNOS, COX-2, and PGE2 in vitro or in mouse skin. Br. J. Pharmacol. 146 (2005) 352-363
28. Geller D.A., and Billiar T.R. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 17 (1998) 7-23
29. Murata J., Tada M., Iggo R.D., Sawamura Y., Shinohe Y., and Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat. Res. 379 (1997) 211-218
30. Satomi Y., Bu P., Okuda M., Tokuda H., and Nishino H. H-ras mutations at codon 61 or 13 in tumors initiated with a NO donor in mouse skin. Cancer Lett. 196 (2003) 17-22
31. Chun K.S., Cha H.H., Shin J.W., Na H.K., Park K.K., Chung W.Y., and Surh Y.J. Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-kB. Carcinogenesis 25 (2004) 445-454
32. Ding Y.B., Chen G.Y., Xia J.G., Zang X.W., Yang H.Y., and Yang L. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J. Gastroenterol. 9 (2003) 1409-1414
33. Wang G.Y., Ji B., and Gu J.H. Anti-cancer effect of iNOS and its correlation with angiogenesis in gastric cancer. World J. Gastroenterol. 11 (2005) 3830-3833
34. Goranov S.E., and Goranova-Marinova V.S. Bortezomib (Belcade)-a new therapeutic strategy for patients with refractory multiple myeloma. Folia. Med. 47 (2005) 11-19
35. Zhou Z., Connell C.M., and MacEwan D.J. TNFR1-induced NF-kB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal. 19 (2007) 1238-1248
36. Dhar A., Young M.R., and Colburn N.H. The role of AP-1, NF-κB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol. Cell. Biochem. 234-235 (2002) 185-193
37. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: How hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
38. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol. 64 (2002) 883-888
39. Strnad J., and Burke J.R. IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol. Sci. 28 (2007) 142-148
40. Kundu J.K., Shin Y.K., and Surh Y.J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-κB and AP-1 as prime targets. Biochem. Pharmacol. 72 (2006) 1506-1515
41. Kim H.G., Shrestha B., Lim S.Y., Yoon D.H., Chang W.C., Shin D.J., Han S.K., Park S.M., Park J.H., Park H.I., Sung J.M., Jang Y., Chung N., Hwang K.C., and Kim T.W. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur. J. Pharmacol. 545 (2006) 192-199
42. Kwon H.M., Choi Y.J., Choi J.S., Kang S.W., Bae J.Y., Kang I.J., Jun J.G., Lee S.S., Lim S.S., and Kang Y.H. Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoloquiritigenin through NF-κB signal disruption. Exp. Biol. Med. 232 (2007) 235-245
43. Lin W.N., Luo S.F., Lee C.W., Wang C.C., Wang J.S., and Yang C.M. Involvement of MAPKs and NF-κB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells. Cell Signal. 19 (2007) 1258-1267
44. Kim W., Moon S.O., Lee S., Sung M.J., Kim S.H., and Park S.K. Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and adhesiveness through a phosphatidylinositol 3'-kinase pathway. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1377-1383